From LiverWiki
(previous 200) (
next 200)
Pages in category "Metabolome"
The following 200 pages are in this category, out of 2,067 total.
(
1
- 1 Methylhistidine (PubChem:92105):Metabolomics Approach to Allograft Assessment in Liver Transplantation (Assay 1)
- 1,11-Bis(trimethylsiloxy)undecane (CHEBI:131330):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,11-Undecanedicarboxylic acid (PubChem:10458):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 1,2,3-Oxadiazolium, 5-mercapto-3-phenyl-, hydroxide, inner salt (CHEBI:131332):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,2,4-benzenetriol (PubChem:10787):Temporal metabolomic responses of cultured HepG2 liver cells to high fructose and high glucose exposures (Assay 1)
- 1,2-Butanediol, bis(trimethylsilyl)- (CHEBI:52682):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,2-Propanediol-1-phosphate, tris(trimethylsilyl)- (CHEBI:18025):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,25-Dihydroxyvitamin D3-26,23-lactone (PubChem:6438368):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 1,3-Dioxolane (CHEBI:87597):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,3-Dioxolane, 2-(1-methylpropyl)- (CHEBI:131333):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,3-Dioxolane, 2-(3-bromo-5,5,5-trichloro-2,2-dimethylpentyl)- (CHEBI:131193):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,3-Dioxolane, 2-(6-heptynyl)- (CHEBI:131334):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,4-Benzenedicarboxylic acid, bis(trimethylsilyl) ester (CHEBI:15702):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,5-anhydroglucitol (PubChem:64960):Metabolic profiling during ex vivo machine perfusion of the human liver (part I) (Assay 1)
- 1,5-cis,8-cis-Undecatriene-3,7-diol bis(trimethylsilyl)ether (CHEBI:131335):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1,8-cis-Undecadien-5-yne 3,7-bis-trimethylsilyl ether (CHEBI:131336):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-(3-Methylbutyl)-2,3,4,6-tetramethylbenzene (CHEBI:131433):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-(Trimethylsilylmethyl)dimethylsilyloxypentane (CHEBI:44884):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Cyclopentyl-1-trimethylsilyloxyethane (CHEBI:131340):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Di(tert-butyl)silyloxypentane (CHEBI:44884):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Di(tert-butyl)silyloxytetradecane (CHEBI:77417):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Methyl-4-imidazoleacetic acid (PubChem:75810):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 1-Methyl-4-imidazoleacetic acid (PubChem:75810):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 1-Methyladenosine (PubChem:27476):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 1-Methyladenosine (PubChem:27476):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 1-Methylhistamine (PubChem:3614):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 1-Methylhistamine (PubChem:3614):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 1-Methylhistidine (PubChem:92105):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 1-Methylhistidine (PubChem:92105):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 1-Methylnicotinamide (PubChem:457):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 1-Methylnicotinamide (PubChem:457):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 1-Monooleoylglycerol trimethylsilyl ether (CHEBI:131342):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Naphthoic acid, 4-nitrophenyl ester (CHEBI:131343):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Pentamethyldisilyloxy-10-undecene (CHEBI:131344):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Pentamethyldisilyloxybutane (CHEBI:28885):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Pentamethyldisilyloxycyclopentane (CHEBI:16133):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Pentamethyldisilyloxypentane (CHEBI:44884):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Propene-1,2,3-tricarboxylic acid, tris(trimethylsilyl) ester, (E)- (CHEBI:32806):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Propene-1-thiol (CHEBI:59723):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-Trimethylsilyloxytetradecane (CHEBI:77417):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1-monopalmitin (PubChem:14900):Metabolic profiling during ex vivo machine perfusion of the human liver (part I) (Assay 1)
- 1-monostearin (PubChem:24699):Metabolic profiling during ex vivo machine perfusion of the human liver (part I) (Assay 1)
- 1-monostearin (PubChem:24699):Temporal metabolomic responses of cultured HepG2 liver cells to high fructose and high glucose exposures (Assay 1)
- 10-HDoHE (CHEBI:72640):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 10-Undecen-1-al, 2-methyl- (CHEBI:131339):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
|
1 cont.
- 10-hydroxy-2E,8E-decadiene-4,6-diynoic acid (CHEBI:72691):LC-MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort (Assay 1)
- 11-HDoHE (CHEBI:72794):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 11-HETE (CHEBI:72606):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 11-Hydroxyeicosatetraenoate glyceryl ester (PubChem:53481455):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 12(13)Ep-9-KODE (PubChem:5283007):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 12,13-DiHODE (CHEBI:88461):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 12,13-DiHOME (CHEBI:72665):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 12,13-EpOME (CHEBI:38299):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 12-HETE (CHEBI:19138):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 12-Ketodeoxycholic acid (PubChem:3080612):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 12S-HEPE (CHEBI:88345):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 12S-HHTrE (CHEBI:63977):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 12a-Hydroxy-3-oxocholadienic acid (PubChem:53477691):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 13,14-Dihydro- lipoxin A4 (PubChem:53481469):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 13,14-Dihydro-15-oxo-lipoxin A4 (PubChem:53481470):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 13-HDoHE (CHEBI:72608):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 13-HODE (CHEBI:72639):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 13-KODE (CHEBI:136531):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 13-OxoODE (PubChem:6446027):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 14,15-DiHETrE (CHEBI:63966):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 14-HDoHE (CHEBI:72647):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 15,16-dihydrobiliverdin (CHEBI:16790):LC-MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort (Assay 1)
- 15-HETE (CHEBI:64017):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 15S-HEPE (CHEBI:88347):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 15S-HETrE (CHEBI:88348):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 16-hydroxy hexadecanoic acid (PubChem:7058075):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 16b-Hydroxystanozolol (PubChem:14299609):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 17,18-DiHETE (CHEBI:88349):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 17-hydroxypregnenolone (PubChem:91451):Perinatal DDT causes dysfunctional lipid metabolism underlying metabolic syndrome (Assay 1)
- 17-hydroxyprogesterone (PubChem:6238):Perinatal DDT causes dysfunctional lipid metabolism underlying metabolic syndrome (Assay 1)
- 19,20-DiHDPA (CHEBI:72657):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 19,20-EpDPE (CHEBI:72653):Metabolic characterization of the natural progression of chronic hepatitis B (Oxylipin assay). (Assay 1)
- 19-Hydroxy-PGE2 (PubChem:5283038):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 1H-1,2,3-Triazole, 4,5-diphenyl- (CHEBI:131341):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1H-Indole-3-acetamide, 1-trimethylsilyl- (CHEBI:16031):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1H-Indole-3-acetic acid, 1-(trimethylsilyl)-, trimethylsilyl ester (CHEBI:16411):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 1H-Indole-3-propanoic acid, 1-(trimethylsilyl)-, trimethylsilyl ester (CHEBI:43580):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
2
- 2,3,4-Trihydroxybutyric acid tetrakis(trimethylsilyl) deriv. (CHEBI:49060):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2,3-Diphosphoglyceric acid (PubChem:186004):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 2,4(1H,3H)-Pyrimidinedione, dihydro-1,3-bis(trimethylsilyl)- (CHEBI:15901):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2,4-hexadienedioic acid NIST (PubChem:5280518):Metabolic profiling during ex vivo machine perfusion of the human liver (part I) (Assay 1)
- 2,5-dihydroxypyrazine NIST (PubChem:23368901):Metabolic profiling during ex vivo machine perfusion of the human liver (part I) (Assay 1)
- 2,6 dimethylheptanoyl carnitine (PubChem:53477823):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 2,6-Octadiene, 1,8-bis(trimethylsilyl)- (CHEBI:111518):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-(4-Methoxyphenyl)-2-(4-trimethoxysilyloxy)propane (CHEBI:131346):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Aminoadipic acid (PubChem:469):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 2-Aminoadipic acid (PubChem:469):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 2-Aminobutyric acid (PubChem:6657):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 2-Aminobutyric acid (PubChem:6657):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 2-Arachidonylglycerol (PubChem:5282280):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 2-Butenedioic acid (E)-, bis(trimethylsilyl) ester (CHEBI:18012):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Butenedioic acid (Z)-, bis(trimethylsilyl) ester (CHEBI:18300):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Butenedioic acid, 2TMS (CHEBI:22958):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Deoxy ribose O,O',O''-tris(trimethylsilyl)- (CHEBI:131350):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Deoxy-galactopyranose, tetrakis(trimethylsilyl) (CHEBI:131352):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Ethyl-3-hydroxypropionic acid, di-TMS (CHEBI:82956):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Ethyl-3-ketovalerate, bis(trimethylsilyl) (CHEBI:131353):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Ethyl-3-trimethylsilyloxy(trimethylsilyl)butyrate (CHEBI:131354):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Ethylacetoacetate, O,O'-bis(trimethylsilyl)- (CHEBI:131199):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Hexaprenyl-3-methyl-6-methoxy-1,4 benzoquinone (PubChem:5280827):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 2-Hexaprenyl-6-methoxy-1,4-benzoquinol (PubChem:53481383):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 2-Hexenoylcarnitine (CHEBI:88762):Metabolic characterization of the natural progression of chronic hepatitis B (Biogenic amine and Acyl-carnitine assays). (Assay 1)
- 2-Hydroxybutyric acid (PubChem:11266):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 2-Hydroxybutyric acid (PubChem:11266):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 2-Hydroxybutyric acid, 2TMS (CHEBI:1148):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 2-Hydroxyglutaric acid (PubChem:43):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 2-Hydroxyglutaric acid (PubChem:43):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
|
2 cont.
3
- 3 (CHEBI:72724):LC-MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort (Assay 1)
- 3 (CHEBI:72727):LC-MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort (Assay 1)
- 3 HBA (PubChem:441):Metabolomics Approach to Allograft Assessment in Liver Transplantation (Assay 1)
- 3 Hydroxy-2,3-didehydrosebacic acid, tris(trimethylsilyl) derivative (CHEBI:131363):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3 Methylhistidine (PubChem:64969):Metabolomics Approach to Allograft Assessment in Liver Transplantation (Assay 1)
- 3, 5-Tetradecadiencarnitine (CHEBI:89746):Metabolic characterization of the natural progression of chronic hepatitis B (Biogenic amine and Acyl-carnitine assays). (Assay 1)
- 3,4,5-Trihydroxypentanoic acid, tetrakis(trimethylsilyl)- (CHEBI:131364):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3,5-Di-tert-butyl-4-trimethylsiloxytoluene (CHEBI:34247):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3,5-Dihydroxyphenylacetic acid, 3TMS (CHEBI:131431):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3,6-Dioxa-2,7-disilaoctane, 2,2,4,4,5,5,7,7-octamethyl- (CHEBI:131185):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3,7-Dioxa-2,8-disilanonan-5-one, 2,2,8,8-tetramethyl- (CHEBI:16016):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-Aminoisobutanoic acid (CHEBI:27389):Metabolic characterization of the natural progression of chronic hepatitis B (Biogenic amine and Acyl-carnitine assays). (Assay 1)
- 3-Aminoisobutyric acid (PubChem:64956):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 3-Aminoisobutyric acid (PubChem:64956):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 3-Butenoic acid, 3-(trimethylsiloxy)-, trimethylsilyl ester (CHEBI:131367):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-Hydroxy-5, 8-tetradecadiencarnitine (PubChem:53481683):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 3-Hydroxy-cis-5-tetradecenoylcarnitine (PubChem:53481679):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 3-Hydroxybenzoic acid, 2TMS (CHEBI:30764):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-Hydroxybutyric acid (PubChem:441):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (Assay 1)
- 3-Hydroxybutyric acid (PubChem:441):Comprehensive analysis of transcriptome and metabolome in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma (part II) (Assay 1)
- 3-Hydroxybutyric acid, 2TMS (CHEBI:20067):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-Hydroxyhexdecanedioyl-CoA (PubChem:53481644):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 3-Hydroxyisobutyrate (CHEBI:11805):Metabolomics profiling of pre-and post-anesthesia plasma samples obtained via Ficoll separation (Assay 1)
- 3-Hydroxyphenylacetic acid, 2TMS (CHEBI:17445):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-Hydroxyphenylpropionic acid, 2TMS (CHEBI:131432):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-Methoxytyramine, TMS (CHEBI:1582):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-Methylcrotonyl-CoA (PubChem:439869):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 3-Methylene-1,4-bis(trimethylsilyloxy) butane (CHEBI:131368):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-O-Sulfogalactosylceramide (d18:1/24:1(15Z)) (PubChem:24779587):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 3-Oxa-6-thia-2,7-disilaoctane, 2,2,7,7-tetramethyl- (CHEBI:41218):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
- 3-Oxo-4,6-choladienoic acid (PubChem:5283992):Cyclobutene- and cyclobutane-functionalized fatty acids as novel biochemical probes of structure and function in HepG2 cells (Assay 1)
- 3-Oxobutanoic acid, TMS (CHEBI:15344):Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease (Assay 1)
|
(previous 200) (
next 200)